KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Operating Leases (2019 - 2025)

Rigel Pharmaceuticals (RIGL) has 7 years of Operating Leases data on record, last reported at $395000.0 in Q4 2025.

  • For Q4 2025, Operating Leases changed N/A year-over-year to $395000.0; the TTM value through Dec 2025 reached $395000.0, changed N/A, while the annual FY2025 figure was $395000.0, N/A changed from the prior year.
  • Operating Leases reached $395000.0 in Q4 2025 per RIGL's latest filing, down from $556000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $12.9 million in Q3 2021 and bottomed at $100000.0 in Q1 2024.
  • Average Operating Leases over 5 years is $2.8 million, with a median of $759000.0 recorded in 2021.
  • Peak YoY movement for Operating Leases: crashed 92.87% in 2021, then skyrocketed 764.0% in 2025.
  • A 5-year view of Operating Leases shows it stood at $759000.0 in 2021, then grew by 28.06% to $972000.0 in 2022, then tumbled by 70.68% to $285000.0 in 2023, then plummeted by 64.91% to $100000.0 in 2024, then surged by 295.0% to $395000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $395000.0 in Q4 2025, $556000.0 in Q3 2025, and $714000.0 in Q2 2025.